GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Shiller PE Ratio

Coherus BioSciences (FRA:8C5) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Coherus BioSciences Shiller PE Ratio Historical Data

The historical data trend for Coherus BioSciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Shiller PE Ratio Chart

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Coherus BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Coherus BioSciences's Shiller PE Ratio

For the Biotechnology subindustry, Coherus BioSciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Shiller PE Ratio falls into.



Coherus BioSciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Coherus BioSciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Coherus BioSciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.764/131.7762*131.7762
=0.764

Current CPI (Mar. 2024) = 131.7762.

Coherus BioSciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.016 100.560 -1.331
201409 -0.191 100.428 -0.251
201412 -1.192 99.070 -1.586
201503 -1.127 99.621 -1.491
201506 -1.390 100.684 -1.819
201509 -1.657 100.392 -2.175
201512 -1.239 99.792 -1.636
201603 -1.500 100.470 -1.967
201606 -1.531 101.688 -1.984
201609 1.488 101.861 1.925
201612 -1.621 101.863 -2.097
201703 -1.440 102.862 -1.845
201706 -0.961 103.349 -1.225
201709 -0.915 104.136 -1.158
201712 -0.710 104.011 -0.900
201803 -0.600 105.290 -0.751
201806 -0.582 106.317 -0.721
201809 -0.746 106.507 -0.923
201812 -0.809 105.998 -1.006
201903 -0.257 107.251 -0.316
201906 0.283 108.070 0.345
201909 0.572 108.329 0.696
201912 0.477 108.420 0.580
202003 0.434 108.902 0.525
202006 0.622 108.767 0.754
202009 0.280 109.815 0.336
202012 0.099 109.897 0.119
202103 -1.991 111.754 -2.348
202106 -0.332 114.631 -0.382
202109 -0.417 115.734 -0.475
202112 -0.531 117.630 -0.595
202203 -1.126 121.301 -1.223
202206 -0.615 125.017 -0.648
202209 -1.121 125.227 -1.180
202212 -0.717 125.222 -0.755
202303 -0.897 127.348 -0.928
202306 -0.452 128.729 -0.463
202309 -0.384 129.860 -0.390
202312 -0.651 129.419 -0.663
202403 0.764 131.776 0.764

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Coherus BioSciences  (FRA:8C5) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Coherus BioSciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences (FRA:8C5) Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines